Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?

Wanrudee Isaranuwatchai, Donna M. Graham, Lillian L. Siu, Jeffrey S Hoch

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Could the human papillomavirus (HPV) vaccination be cost-effective in males for the prevention of oropharyngeal squamous cell cancer (OPC)? It could be under certain conditions. Research on HPV vaccine has focused mainly on females. However, within the next decade, it is predicted that OPC will surpass cervical cancer as the most common HPV-related cancer, and it is postulated that HPV vaccination may alter the incidence of OPC. The purpose of this editorial is to comment on the potential cost-effectiveness of HPV vaccination in males for OPC prevention by addressing three elements payers often consider when making a decision to fund an intervention and to provide an overview of recent findings regarding the cost-effectiveness of HPV vaccine in males.

Original languageEnglish (US)
Pages (from-to)763-765
Number of pages3
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume14
Issue number6
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Oropharyngeal Neoplasms
Vaccination
Costs and Cost Analysis
Papillomavirus Vaccines
Cost-Benefit Analysis
Squamous Cell Neoplasms
Financial Management
Uterine Cervical Neoplasms
Decision Making
Incidence
Research
Neoplasms

Keywords

  • Cost-effectiveness analysis
  • Economic evaluation
  • Human papillomavirus
  • Oropharyngeal cancer
  • Vaccine

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health Policy
  • Medicine(all)

Cite this

Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer? / Isaranuwatchai, Wanrudee; Graham, Donna M.; Siu, Lillian L.; Hoch, Jeffrey S.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 14, No. 6, 01.12.2014, p. 763-765.

Research output: Contribution to journalReview article

@article{6ba44a78f6874ec08b1799b30f7da8ac,
title = "Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?",
abstract = "Could the human papillomavirus (HPV) vaccination be cost-effective in males for the prevention of oropharyngeal squamous cell cancer (OPC)? It could be under certain conditions. Research on HPV vaccine has focused mainly on females. However, within the next decade, it is predicted that OPC will surpass cervical cancer as the most common HPV-related cancer, and it is postulated that HPV vaccination may alter the incidence of OPC. The purpose of this editorial is to comment on the potential cost-effectiveness of HPV vaccination in males for OPC prevention by addressing three elements payers often consider when making a decision to fund an intervention and to provide an overview of recent findings regarding the cost-effectiveness of HPV vaccine in males.",
keywords = "Cost-effectiveness analysis, Economic evaluation, Human papillomavirus, Oropharyngeal cancer, Vaccine",
author = "Wanrudee Isaranuwatchai and Graham, {Donna M.} and Siu, {Lillian L.} and Hoch, {Jeffrey S}",
year = "2014",
month = "12",
day = "1",
doi = "10.1586/14737167.2014.946012",
language = "English (US)",
volume = "14",
pages = "763--765",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Could the human papillomavirus vaccination be cost-effective in males for the prevention of oropharyngeal cancer?

AU - Isaranuwatchai, Wanrudee

AU - Graham, Donna M.

AU - Siu, Lillian L.

AU - Hoch, Jeffrey S

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Could the human papillomavirus (HPV) vaccination be cost-effective in males for the prevention of oropharyngeal squamous cell cancer (OPC)? It could be under certain conditions. Research on HPV vaccine has focused mainly on females. However, within the next decade, it is predicted that OPC will surpass cervical cancer as the most common HPV-related cancer, and it is postulated that HPV vaccination may alter the incidence of OPC. The purpose of this editorial is to comment on the potential cost-effectiveness of HPV vaccination in males for OPC prevention by addressing three elements payers often consider when making a decision to fund an intervention and to provide an overview of recent findings regarding the cost-effectiveness of HPV vaccine in males.

AB - Could the human papillomavirus (HPV) vaccination be cost-effective in males for the prevention of oropharyngeal squamous cell cancer (OPC)? It could be under certain conditions. Research on HPV vaccine has focused mainly on females. However, within the next decade, it is predicted that OPC will surpass cervical cancer as the most common HPV-related cancer, and it is postulated that HPV vaccination may alter the incidence of OPC. The purpose of this editorial is to comment on the potential cost-effectiveness of HPV vaccination in males for OPC prevention by addressing three elements payers often consider when making a decision to fund an intervention and to provide an overview of recent findings regarding the cost-effectiveness of HPV vaccine in males.

KW - Cost-effectiveness analysis

KW - Economic evaluation

KW - Human papillomavirus

KW - Oropharyngeal cancer

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=84909950629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84909950629&partnerID=8YFLogxK

U2 - 10.1586/14737167.2014.946012

DO - 10.1586/14737167.2014.946012

M3 - Review article

C2 - 25095728

AN - SCOPUS:84909950629

VL - 14

SP - 763

EP - 765

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 6

ER -